Comprehensive Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer in the Era of Precision Medicine: Construction and Optimization of the MDT Decision-Making System

In the context of the rapid advancement of precision medicine, the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) has shifted toward individualized approaches. However, it faces challenges such as extended lines of therapy, complex resistance mechanisms, and the widespread adoption of immunotherapy combinations. A single discipline can no longer meet the demands of comprehensive precision management throughout the disease course. Consequently, the multidisciplinary team (MDT) model has evolved from traditional discussions into a systematic and dynamic decision-making framework. This article focuses on EGFR mutation-positive NSCLC to explore the construction and optimization of the MDT system. Core elements include team structure and process design, dynamic reassessment mechanisms, the establishment of information-sharing platforms, and innovative decision-making models that integrate immunotherapy and local therapies. Drawing on the latest research, MDT has demonstrated potential in enhancing the consistency of treatment decisions, prolonging patient survival, and improving the treatment experience. Furthermore, this article proposes that by leveraging digital technology, fostering regional collaboration mechanisms, and implementing standardized quality control systems, the development of a "learning-type MDT" system can be promoted. Such advancements will contribute to achieving comprehensive precision management throughout the entire course of EGFR mutation-positive NSCLC, thereby facilitating the deep application and clinical translation of precision medicine in lung cancer treatment.